NRx Pharmaceuticals

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI

RADNOR, PA — NRx Pharmaceuticals (Nasdaq: NRXP) announced this week that it has completed an analysis to identify clinical evidence that indicates a substantial improvement after treatment with ZYESAMI® (aviptadil) …

NRx Pharmaceuticals Identifies Significantly Higher Likelihood of Surviving and Recovering from Critical COVID-19 in ZYESAMI Read More